高橋 遼平 (タカハシ リョウヘイ)

Takahashi, Ryohei

写真a

所属(所属キャンパス)

医学部 泌尿器科学教室 (信濃町)

職名

助教(有期)

プロフィール 【 表示 / 非表示

  • 泌尿器分野の研究を行っております

経歴 【 表示 / 非表示

  • 2011年04月
    -
    2013年03月

    さいたま市立病院, 初期臨床研修医

  • 2013年04月
    -
    2014年03月

    慶應義塾大学医学部, 泌尿器科学教室, 助教

  • 2014年04月
    -
    2015年03月

    国家公務員共済組合連合会 立川病院, 泌尿器科, 医員

  • 2015年04月
    -
    2016年03月

    東京都立小児総合医療センター, 泌尿器科, 医員

  • 2016年04月
    -
    2017年03月

    東京歯科大学市川総合病院, 泌尿器科, 助教

全件表示 >>

学歴 【 表示 / 非表示

  • 2005年04月
    -
    2011年03月

    慶應義塾, 医学部, 医学科

    日本, 大学, 卒業

免許・資格 【 表示 / 非表示

  • 緩和ケア研修, 2012年07月

  • 日本泌尿器科学会専門医, 2017年10月

 

研究分野 【 表示 / 非表示

  • 泌尿器科学

  • 免疫学

 

論文 【 表示 / 非表示

  • Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy

    Takamatsu K., Tanaka N., Hakozaki K., Takahashi R., Teranishi Y., Murakami T., Kufukihara R., Niwa N., Mikami S., Shinojima T., Sasaki T., Sato Y., Kume H., Ogawa S., Kakimi K., Kamatani T., Miya F., Tsunoda T., Aimono E., Nishihara H., Sawada K., Imamura T., Mizuno R., Oya M.

    Nature Communications (Nature Communications)  12 ( 1 )  2021年12月

     概要を見る

    A cutting edge therapy for future immuno-oncology is targeting a new series of inhibitory receptors (IRs): LAG-3, TIM-3, and TIGIT. Both immunogenomic analyses and diagnostic platforms to distinguish candidates and predict good responders to these IR-related agents are vital in clinical pathology. By applying an automated single-cell count for immunolabelled LAG-3, TIM-3, and TIGIT, we reveal that individual IR levels with exclusive domination in each tumour can serve as valid biomarkers for profiling human renal cell carcinoma (RCC). We uncover the immunogenomic landscape associated with individual IR levels in human RCC tumours with metastases in various organs and histological subtypes. We then externally validate our results and devise a workflow with optimal biomarker cut-offs for discriminating the LAG-3, TIM-3, and TIGIT tumour profiles. The discrimination of LAG-3, TIM-3, and TIGIT profiles in tumours may have a broad impact on investigations of immunotherapy responses after targeting a new series of IRs.

  • Safety and efficacy of plasma exchange via direct femoral vein puncture in autoimmune blistering diseases

    Yoshida T., Minakuchi H., Takahashi R., Morita S., Oya M.

    Journal of Clinical Apheresis (Journal of Clinical Apheresis)  35 ( 3 ) 172 - 177 2020年06月

    ISSN  07332459

     概要を見る

    © 2020 Wiley Periodicals, Inc. Plasma exchange (PE) is performed for patients with autoimmune blistering diseases by using multiple vascular access routes. We retrospectively examined the safety and the efficacy of PE using direct femoral vein puncture (FVP) technique, by comparing with that using double-lumen catheter (DLC). The troubles related to vascular route, such as catheter occlusion, insufficient blood flow and hematoma, were not different between the FVP group (4.6%) and the DLC group (6.7%), whereas access-related infections occurred more frequently in the DLC group (6.7%) than the FVP group (0.4%). Regarding the efficacy, the removal rate of autoantibodies in PE using the FVP technique was similar or lower, as compared with that using the DLC. These results suggest that PE with the FVP technique is able to be performed safely in patients with autoimmune blistering diseases, although the removal of autoantibodies is not superior to that using the DLC.

  • Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report

    Shinoda K., Morita S., Tamaki S., Takahashi R., Kitaoka S., Asanuma H., Yoshida T., Okayama M., Kasahara H., Okamoto S., Oya M.

    Transplantation Proceedings (Transplantation Proceedings)  52 ( 2 ) 604 - 607 2020年

    ISSN  00411345

     概要を見る

    © 2020 Elsevier Inc. Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib.

  • Acute scrotum in children: Surgical indication and procedures

    Asanuma H., Takahashi R., Oya M.

    Japanese Journal of Clinical Urology (Japanese Journal of Clinical Urology)  74 ( 7 ) 472 - 477 2020年

    ISSN  03852393

  • Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: A case report and literature review

    Takahashi R., Shinoda K., Ishida T., Hamamoto Y., Morita S., Akita H., Kitaoka S., Tamaki S., Asanuma H., Yoshida T., Jinzaki M., Kameyama K., Oya M.

    BMC Nephrology (BMC Nephrology)  20 ( 1 )  2019年04月

     概要を見る

    © 2019 The Author(s). Background: Gastrointestinal stromal tumors (GISTs) in transplant recipients are very rare and only a handful of cases have been reported to date. Here we present the first known case of a huge GIST in a kidney transplant recipient with perforation of small intestine. Case presentation: A 64-year-old male presented at our hospital with right colic pain; he had received an ABO incompatible kidney transplant 6 years earlier and was treated with cyclosporine, mycophenolate mofetil, and methylprednisolone. Radiological evaluation revealed a huge (11 cm in diameter) solitary tumor at the small intestine without distant metastasis. The small intestinal wall at the tumor location was perforated one week after diagnosis and the patient underwent emergency surgery. The pathological findings were compatible with GIST and the tumor consisted of spindle cells with positive staining for KIT, CD34, and DOG1 and negative or weak staining for desmin and S-100 protein. A mutation in exon 11 of the c-kit gene was also detected. Cyclosporine was withdrawn and imatinib mesylate (400 mg daily) was introduced. However, thereafter, we needed to decrease the dose at 300 mg daily due to severe hyponatremia. Reduced imatinib treatment was well tolerated and recurrence was not observed for 18 months after surgery. Conclusions: The occurrence of GISTs in transplant patients is rare, and huge GISTs should be resected immediately after diagnosis because gastrointestinal tract at the tumor site could be perforated. Imatinib treatment is feasible in transplant recipients under immunosuppression, although immunosuppressive drugs metabolized by CYP3A4 should be used at a reduced dosage or withdrawn.

全件表示 >>

研究発表 【 表示 / 非表示

  • 当院における悪性腫瘍既往歴のある腎移植についての検討

    第57回日本移植学会, 2021年09月, 口頭(一般)

  • 尿管狭窄に対して口腔粘膜を利用し尿路再建を行った一例

    第30回小児泌尿器科学会, 2021年07月, 口頭(一般)

  • 生体腎移植後に直腸カルチノイドを発症した1例

    第36回腎移植血管外科学会, 2021年06月, 口頭(一般)

  • 当院で行っている腎移植後悪性腫瘍スクリーニングの検討

    第54回臨床腎移植学会, 2021年02月, 口頭(一般)

  • 当院における小児尿路結石症の治療成績

    第29回小児泌尿器科学会, 2021年01月, 口頭(一般)

全件表示 >>